Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$25.40
-0.4%
$25.84
$16.54
$28.67
$378.13M0.7459,299 shs40,593 shs
Atrion Co. stock logo
ATRI
Atrion
$465.25
+2.1%
$425.39
$274.98
$602.59
$818.84M0.6231,461 shs38,821 shs
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$20.00
$19.98
$12.26
$20.57
$843.96M0.74765,906 shs4,300 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$4.92
-5.9%
$5.84
$4.38
$8.45
$363.88M0.23787,015 shs1.00 million shs
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-0.39%-0.90%-1.13%+4.92%-2.38%
Atrion Co. stock logo
ATRI
Atrion
+2.06%+4.47%+16.67%+32.10%-17.14%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.00%0.00%0.00%0.00%0.00%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-5.93%+1.23%-6.29%-27.11%-9.39%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
3.1384 of 5 stars
2.31.00.03.61.61.71.9
Atrion Co. stock logo
ATRI
Atrion
1.419 of 5 stars
0.01.02.50.02.03.31.3
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.9068 of 5 stars
3.21.00.04.21.61.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
2.50
Moderate Buy$29.5016.14% Upside
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/A
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.33
Hold$6.6334.65% Upside

Current Analyst Ratings

Latest ATRI, CSII, OSUR, and ANIK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2024
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$7.00 ➝ $6.00
5/9/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$37.00 ➝ $37.00
4/4/2024
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$7.00 ➝ $6.50
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$22.00
3/14/2024
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$29.00 ➝ $37.00
(Data available from 5/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
$166.66M2.26$4.90 per share5.18$14.06 per share1.81
Atrion Co. stock logo
ATRI
Atrion
$169.33M4.84$20.01 per share23.25$137.46 per share3.38
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
$239.84M3.52N/AN/A$6.12 per share3.27
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$405.47M0.90$1.26 per share3.90$5.76 per share0.85

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$82.67M-$5.25N/A19.242.36-45.39%0.48%0.39%8/13/2024 (Estimated)
Atrion Co. stock logo
ATRI
Atrion
$19.41M$10.6443.73N/A10.60%7.75%7.12%8/13/2024 (Estimated)
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
-$36.93M-$0.97N/AN/AN/A-15.79%-15.39%-11.93%N/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$53.65M$0.3016.40N/AN/A7.50%7.68%6.83%8/1/2024 (Estimated)

Latest ATRI, CSII, OSUR, and ANIK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/10/2024Q1 2024
Atrion Co. stock logo
ATRI
Atrion
N/A$1.59+$1.59$1.59N/A$47.33 million
5/8/2024Q1 2024
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$0.04$0.04N/A$0.05$52.27 million$54.10 million    
3/13/2024Q4 2023
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
-$0.15$0.05+$0.20$4.40$41.51 million$42.97 million
2/29/2024Q4 2023
Atrion Co. stock logo
ATRI
Atrion
N/A$3.65+$3.65$3.65N/A$43.58 million
2/27/2024Q4 2023
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$0.13$0.22+$0.09$0.17$74.13 million$75.88 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/AN/AN/AN/AN/A
Atrion Co. stock logo
ATRI
Atrion
$8.801.89%+9.65%82.71%21 Years
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A

Latest ATRI, CSII, OSUR, and ANIK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/27/2024
Atrion Co. stock logo
ATRI
Atrion
Quarterly$2.202.42%3/14/20243/15/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
N/A
5.59
3.85
Atrion Co. stock logo
ATRI
Atrion
N/A
9.18
2.57
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
0.08
6.04
4.92
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
11.97
10.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
91.53%
Atrion Co. stock logo
ATRI
Atrion
66.19%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
86.61%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%

Insider Ownership

CompanyInsider Ownership
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
5.85%
Atrion Co. stock logo
ATRI
Atrion
22.82%
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
3.80%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Anika Therapeutics, Inc. stock logo
ANIK
Anika Therapeutics
35714.83 million13.96 millionOptionable
Atrion Co. stock logo
ATRI
Atrion
7121.76 million1.36 millionNot Optionable
Cardiovascular Systems, Inc. stock logo
CSII
Cardiovascular Systems
78042.20 million40.59 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
63873.96 million71.44 millionOptionable

ATRI, CSII, OSUR, and ANIK Headlines

Recent News About These Companies

OraSure Technologies (NASDAQ:OSUR) PT Lowered to $6.00
Q1 2024 OraSure Technologies Inc Earnings Call
OraSure: Q1 Earnings Snapshot
OraSure Reports Q1 ’24 Revenue of $54.1 Million

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Anika Therapeutics logo

Anika Therapeutics

NASDAQ:ANIK
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Atrion logo

Atrion

NASDAQ:ATRI
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
Cardiovascular Systems logo

Cardiovascular Systems

NASDAQ:CSII
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. It offers orbital atherectomy systems for both peripheral and coronary commercial applications. The company was founded in 1989 and is headquartered in St. Paul, MN.
OraSure Technologies logo

OraSure Technologies

NASDAQ:OSUR
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.